Barclays Upgrades Roche (OTCMKTS:RHHBY) to “Overweight”

Roche (OTCMKTS:RHHBY) was upgraded by Barclays from an “equal weight” rating to an “overweight” rating in a research report issued on Tuesday.

A number of other equities analysts also recently issued reports on the company. Zacks Research downgraded Roche from a “hold” rating to a “strong sell” rating in a research report on Friday, December 5th. Jefferies Financial Group cut shares of Roche from a “hold” rating to a “moderate sell” rating in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Hsbc Global Res raised Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 2nd. Finally, Morgan Stanley restated an “underweight” rating on shares of Roche in a research note on Tuesday, December 2nd. Three research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $57.00.

Roche Stock Performance

Shares of RHHBY traded up $0.70 during trading hours on Tuesday, reaching $52.07. 501,878 shares of the company traded hands, compared to its average volume of 1,189,733. The stock’s fifty day moving average price is $47.71 and its 200 day moving average price is $43.57. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.80. Roche has a 12-month low of $34.75 and a 12-month high of $53.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RHHBY. Confluence Investment Management LLC lifted its holdings in shares of Roche by 6.4% during the fourth quarter. Confluence Investment Management LLC now owns 18,649 shares of the company’s stock worth $962,000 after purchasing an additional 1,123 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Roche by 22.9% in the 4th quarter. GAMMA Investing LLC now owns 23,235 shares of the company’s stock valued at $1,198,000 after acquiring an additional 4,336 shares during the last quarter. Hancock Whitney Corp increased its stake in shares of Roche by 4.8% in the third quarter. Hancock Whitney Corp now owns 24,488 shares of the company’s stock worth $1,024,000 after acquiring an additional 1,116 shares during the period. Verity Asset Management Inc. raised its holdings in shares of Roche by 20.9% during the third quarter. Verity Asset Management Inc. now owns 10,990 shares of the company’s stock worth $459,000 after purchasing an additional 1,898 shares during the last quarter. Finally, Douglass Winthrop Advisors LLC acquired a new position in Roche during the third quarter valued at $201,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.